This phase II bridging study assessed the safety and efficacy of nab-paclitaxel/gemcitabine (Metastatic Pancreatic Adenocarcinoma Clinical Trial [MPACT] regimen) in Chinese patients with metastatic pancreatic cancer (MPC).
This 3-part sequential study evaluated nab-paclitaxel 125 mg/m2 plus gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 4 weeks. Part 1 evaluated safety. Part 2 evaluated efficacy using Simon’s optimal 2-stage design: if >2 responses were observed in Stage 1 (n = 28), 54 additional patients would be enrolled in Stage 2. If >9 responses were observed, the study was complete. Otherwise, nab-paclitaxel/gemcitabine would be compared with gemcitabine alone in Part 3. The primary endpoint was overall response rate (ORR). Secondary endpoints included duration of response (DOR), overall survival (OS), and safety.
Eighty-three patients were treated. The prespecified primary endpoint was met: the independently assessed ORR in Stages 1 + 2 was 35% (95% CI, 24.8–46.2); therefore, Part 3 was not initiated. The median DOR was 8.9 months (95% CI, 6.01–8.94). The median OS and progression-free survival were 9.2 (95% CI, 7.6–11.1) and 5.5 (95% CI, 5.29–7.16) months, respectively. The 12-month OS rate was 30%. In an updated analysis, the median OS was 9.3 months and the 12-month OS rate was 32%. Longer OS was observed in patients with baseline neutrophil-to-lymphocyte ratio ≤ 5 vs > 5. The most common grade ≥ 3 adverse events were leukopenia (35%), neutropenia (34%), anemia (15%), thrombocytopenia (10%), and fatigue (13%). Grade 3 peripheral neuropathy occurred in 7% of patients (no grade 4 reported).
The MPACT regimen of nab-paclitaxel/gemcitabine is efficacious in Chinese patients with MPC. No new safety signals were observed.
NCT02135822, May 8, 2014.
World Health Organization. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed 17 Sept 2015.
Abraxane for injectable suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound). Summit, NJ: Celgene Corporation. 2015.
European Medicines Agency. Summary of opinion: Abraxane. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/000778/WC500155465.pdf. Accessed 21 Nov 2013.
Goldstein D, El-Maraghi RH, Hammel P, Heinemann V, Kunzmann V, Sastre J, et al. Nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst. 2015;107(2) https://doi.org/10.1093/jnci/dju413.
NCCN Clinical Practice Guidelines in Oncology. Pancreatic Adenocarcinoma. V1.2016. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site. Accessed 15 July 2012.
Ling WH, Lee SC. Inter-ethnic differences–how important is it in cancer treatment? Ann Acad Med Singap. 2011;40(8):356–61. PubMed
Dattani N, Altham D, Coady K. Neutropenia in Asian patients with solid tumors receiving chemotherapy: a retrospective case-control study. J Solid Tumors. 2016;6(2):25–9. CrossRef
Guan Z-Z, Li QL, Feng F, Jiang Z, Shen Z, Yu S, et al. Superior efficacy of a Cremophor-free albumin-bound paclitaxel compared with solvent-based paclitaxel in Chinese patients with metastatic breast cancer. Asia Pac J Clin Oncol. 2009;5(3):165–74. CrossRef
Kasuga A, Ueno H, Ikeda M, Ueno M, Mizuno N, Ioka T, et al. Efficacy, safety and pharmacokinetics of weekly nab-paclitaxel plus gemcitabine in Japanese patients with metastatic pancreatic cancer (MPC): phase I/II trial. Presented at: APA/JPS 45th Anniversary Meeting; November 5–8, 2014; Big Island, HI, USA [abstr. 14200].
Shen L, Hao J, Wang L, Pan H, Han G, Xu J, et al. A phase II study of Chinese patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine for metastatic pancreatic cancer (MPC). J Clin Oncol. 2016;34(4) [abstr. 327].
- Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study
- BioMed Central
Neu im Fachgebiet Onkologie
Mail Icon II